Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Oklahoma
Baylor College of Medicine
Dana-Farber Cancer Institute
University of Miami
Dartmouth-Hitchcock Medical Center
Essen Biotech
GeoVax, Inc.
University of Utah
UNC Lineberger Comprehensive Cancer Center
Colorado State University
University Hospital, Montpellier
Brown University
Washington University School of Medicine
VA Office of Research and Development
Zhongnan Hospital
AC Camargo Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Nebraska
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
National Cancer Institute (NCI)
St. Louis University
M.D. Anderson Cancer Center
Monash University
Monash University
Monash University
National Institutes of Health Clinical Center (CC)
University Hospital, Angers
University of Alabama at Birmingham
National Cancer Institute (NCI)